CTLA4 and hepatocellular carcinoma: This is supported by an increase in the abundance of CD4+ and CD8+ T cells, alongside increased T cell receptor diversity, following anti-CTLA4 therapy in HCC [120]; increased abundance of T cells occurs from restoring the balance between regulatory and effector compartments within the TME [113,121].